

**PROCEDURA VALUTATIVA AI SENSI DELL'ART. 24, COMMA 5, DELLA LEGGE N. 240/2010 AD UN POSTO DI PROFESSORE UNIVERSITARIO DI RUOLO DI SECONDA FASCIA, PRESSO IL DIPARTIMENTO DI BIOLOGIA DELL'UNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA" PER IL SETTORE CONCORSUALE 06/A2 E PER IL SETTORE SCIENTIFICO DISCIPLINARE MED/04.**

**VERBALE N. 2 – VALUTAZIONE**

*(ndr. con svolgimento della prova di idoneità didattica nello stesso giorno)*

Il giorno 16/06/2022 alle ore 10:00 si è riunita in via telematica la commissione di valutazione della procedura in oggetto per la valutazione dell'attività didattica, di didattica integrativa, di servizio agli studenti e delle attività di ricerca scientifica nonché delle pubblicazioni scientifiche eventualmente elaborate dal ricercatore successivamente alla data di scadenza del bando in base al quale ha conseguito l'abilitazione scientifica nazionale, sì da verificare la continuità della produzione scientifica.

Ciascuno dei Commissari dichiara, ai sensi dell'art.5, comma 2, del D.L.gs 1172/1948, di non avere un grado di parentela o affinità entro il quarto grado incluso con il candidato e che non sussistono situazioni di incompatibilità tra essi ed il ricercatore, ai sensi degli articoli 51 e 52 c.p.c.

La commissione prende atto che il candidato, Dott. Michelangelo Campanella, presa visione dei criteri di valutazione stabiliti dalla commissione nella prima seduta tenutasi in data 10/05/2022, ha comunicato l'accettazione dei suddetti criteri, come da nota dell'Ufficio Concorsi dell'Università.

La commissione, quindi, passa ad esaminare la documentazione presentata dal Dott. Campanella e resa disponibile con modalità telematiche.

I commissari si impegnano a trattare la documentazione esclusivamente nell'ambito della presente procedura.

Dopo ampio esame collegiale (anche in base alle dichiarazioni espresse in proposito dai commissari coautori) la commissione si dichiara in grado di enucleare il contributo personale del candidato in relazione alle pubblicazioni redatte in collaborazione con i commissari (7 con il Prof. Pinton, 1 con il Prof. De Maria Marchiano) come importante, sia a livello di contributo sperimentale che di apporto alla discussione dei risultati.

Per quanto riguarda le pubblicazioni redatte in collaborazione con i terzi, dopo ampio esame collegiale, la commissione, tenuto conto della attività scientifica globale e del fatto di essere l'autore principale in un numero di pubblicazioni molto ampio, ritiene di poter enucleare il contributo dato dal candidato come determinante, e decide di accettare tutti i lavori in parola ai fini della successiva valutazione di merito.

**Breve curriculum del candidato Michelangelo Campanella**

1996-2001: Doctor in Pharmacy, University of Ferrara, Italy, date of award 16<sup>th</sup> July 2001

2002-: National Board Pharmacists

2002-2005: PhD in "Cellular and Molecular Pharmacology" University of Ferrara, Italy Supervisor Prof. Rosario Rizzuto, date of award 16<sup>th</sup> July 2005

2005: Academia dei Lincei/Royal Society Short Research Fellow, Department of Physiology and Centre for Clinical Pharmacology and Therapeutics, UCL, UK.



2005-: Member of the Royal Pharmaceutical Society

2005 - 2008: EMBO/Marie Curie Postdoctoral Research Fellow, Department of Physiology and Centre for Clinical Pharmacology and Therapeutics, UCL, UK

2008-2014: Lecturer in Pharmacology (HEFCE funded Tenured post), Department of Comparative Biomedical Science, RVC, University of London, UK

2010 -: Unit Head of the Mitochondrial Cell Biology and Pharmacology (MCP) Research Group Affiliated to the Consortium for Mitochondrial Research (CfMR), University College London, UK

2010-2014: Programme Leader, European Brain Research Institute (EBRI), Rome

2010-: Local Ambassador of the Biochemical Society

2011-: Postgraduate Certificate in Academic Practice in Higher Education (PGCAP), KCL, UK

2012-: Fellow of the Higher Education Academy (FHEA)

2014-2017: Group Leader and Adjunct Professor, Pharmacy Degree Course, Centre of Pharmaceutical Biotechnology, Department of Biology, University of Rome "Tor Vergata"

2014-2018: Reader in Pharmacology (HEFCE funded Tenured post), Department of Comparative Biomedical Sciences, RVC, University of London, UK

2016-: Head of the RVC Oncology Group, University of London, UK

2016-: Fellow of the Royal Society of Biology (FRSB)

2018-: Professor of Pharmacology (HEFCE funded Tenured post, Leave of Absence from 2019), Department of Comparative Biomedical Sciences, RVC, University of London, UK

2019-: Assistant Professor, Department of Biology, University of Rome "Tor Vergata"

### **Attività didattica, di didattica integrativa e di servizio agli studenti**

- Titolare dell'insegnamento in *Mitochondrial Mechanisms of Therapy Resistance* (Corso di Laurea Magistrale in Farmacia) 2 CFU.
- Titolare dell'insegnamento in *Applied Physiopathology* (Corso di Laurea Magistrale in Biotecnologia) per un carico di 3 CFU.
- Membro componente di commissioni di esame per i corsi di *Patologia Generale e Patologia Clinica* (Corso di Laurea Triennale in Scienze Biologiche), (Corso di Laurea Triennale in Biotecnologie), (Corso di Laurea Magistrale Biologia Cellulare E Molecolare E Scienze Biomediche).
- Presidente di commissione di esame per gli insegnamenti in *Mitochondrial Mechanisms of Therapy Resistance* (Corso di Laurea Magistrale in Farmacia) e *Applied Physiopathology* (Corso di Laurea Magistrale in Biotecnologia).



- Relatore di Tesi di Laurea Magistrale in Farmacia (candidato: Nima Daneshvar Baghbadorani conseguimento della laurea previsto in gennaio 2022).
- Relatore di Tesi di Laurea Magistrale in Farmacia (candidata: Parmis Vafadar, conseguimento della laurea previsto per marzo 2022).
- Membro componente della Scuola di Dottorato di Biologia Cellulare e Molecolare – Dip. Biologia.
- Membro componente della Scuola di Dottorato in Immunologia, Medicina Molecolare e Biotecnologia – Dip. Medicina e Chirurgia / Medicina dei Sistemi.
- Attività didattica alla Scuola di Dottorato in Biologia Cellulare e Molecolare – Dip. Biologia con una lezione “*Getting your research funded: Why and How*”, 25-06-2021.
- Supervisor dello studente Manuel Rigon della scuola di Dottorato di Biochimica e Biologia Molecolare (data inizio: novembre 2020)
- Supervisor della studentessa Krenare Bruqui della scuola di Dottorato in Biologia Cellulare e Molecolare (data inizio: Novembre 2021).

## Attività di ricerca

L'attività di ricerca svolta dal Dott. Campanella è prevalentemente orientata allo studio del metabolismo mitocondriale, al ruolo dei mitocondri in una serie di condizioni patologiche ed alla manipolazione farmacologica e genetica del metabolismo mitocondriale a fini terapeutici. Oltre che dalle molteplici pubblicazioni su riviste di alto profilo internazionale (elenco in allegato), tale attività è meglio documentata dalla capacità di attrarre numerosi e cospicui finanziamenti, per un valore complessivo di oltre 12 M euro nell'arco di circa 10 anni, come qui di seguito riportato:

1. CAST Programme 2020. Develop a new COVID-19 Targeting Protocol by repressing cytotoxicity. (01/10/2021-30/11/2021), ~ £ 250,000.
2. BBSRC Alert Grant 2019. Super-Resolution Microscopy of live cells in 3D. (01/10/2020-31/09/2021), ~£ 738,405.
3. Concept Development Funds (CDF) Award 2019. Insight into the molecular mechanisms of mito-nuclear tethering in neurodegeneration to identify novel therapeutic targets. (01/04/2020-31/03/2022), ~£ 100,000.
4. GIME Pilot Grant 2019. Role of the Mitochondrial Ca<sup>2+</sup> Signalling in BAP1 homeostatic function. (01/10/2019-30/09/2020), ~£ 40.000
5. European Research Council (ERC) Consolidator Grant Award 2018. Form and Function of the Mitochondrial Retrograde Response (FIRM) (01/04/2019-31/10/2024), ~€1,500,000.
6. My First AIRC Grant 2018. Revealing Form and Function of the CRIMNL in Breast Cancer (01/04/2019-31/03/2023), ~€ 500,000.
7. LIDO\_BBSRC Studentship. Role of the mito-nuclear interaction in neuronal development. Co-supervisor: Prof. Gyuri Szabadkai. (01/10/2019-30/09/2023), ~£ 115.000.
8. LIDO\_BBSRC-iCase Studentship. Is the epigenetic clock accelerated by mitochondrial reprogramming via mtDNA heteroplasmy and deemed quality control? Co-supervisors: Dr. Camilla Benfield. (01/10/2019-30/09/2023), ~£ 145.000.
9. BBSRC Project Grant (NIH-RO1 Equivalent). The Resilient Brain. Imaging Biomarkers of Brain Metabolic Reserve. (01/05/2016-30/04/2019), ~£ 460,000.
10. PetPlan Charitable Trust. Full Research Grant. Chemo-targeting of TSPO to validate Endocrine Therapy in Canine Mammary Tumours (01/05/2017-01/06/2019), Co-PI with Prof. Ken Smith. ~£ 85,000.



11. BBSRC-iCase Studentship. Bioactive targets of mitochondrial quality control and function. (01/10/2016-30/09/2020), ~£ 140.000.
12. MRC PET-Methodology Award (NIH-R21 Equivalent). The 18-kDa Protein TSPO in the Physiology of Neuronal Cells: Elucidating the Functional Biology of a Consolidated Neuroimaging Tool. Co-Pi with Prof. Federico Turkheimer. (01/02/2014-01/08/2015), ~£ 160.000.
13. Sparks Project Grant. Towards treating the metabolic defect in Late Infantile Neuronal Ceroid Lipofuscinosis. (01/02/2014-01/02/2016). Co-Pi with Dr. Claire Russell. ~£ 115,000.
14. Umberto Veronesi Foundation-Investigator Award. "Molecular Mechanisms of Neuronal Ageing: Regulation of Mitophagy by the Atpif1/Tspo Pathway. (01/04/2014-01/04/2016), ~€ 100,000.
15. MIUR-Futuro in Ricerca, Consolidator Grant (NIH-RO1 Equivalent). "Role of the ATP1F1/Type 2 transglutaminase (TG2) Molecular Axis in the Regulation of Cellular Mitophagy". (01/04/2014-01/04/2017), ~€ 500,000.
16. Ministry of Health of Italy, Young Investigators Programme. "The 18kDa Protein TSPO is a VDAC Dependent Pathway for Metabolic Re-adaptation and Mitophagy Evasion in Glioblastoma". (01/04/2014-01/04/2017), ~€ 450,000.
17. FP7 Marie Curie Actions, CIG. Role of the mitochondrial Translocator Protein (mTSPO) in Brain Physiology. (01/11/2012-01/11/2016), ~€100,000.
18. BBSRC New Investigator Award Grant (NIH-RO1 Equivalent). Role of the mitochondrial Translocator Protein (mTSPO) in cell homeostasis: a molecular pathway in signalling and self-conservatory mechanisms". (07/11/2011-06/11/2014). ~£ 500,000.
19. LAM Research Grant of Research in Brain Tumors. (01/10/2011-31/09/2014) ~€ 150,000. EBRI, Rita Levi Montalcini Foundation- Programme Grant. Metabolism in Brain Diseases. (01/01/2011-31/12/2014), ~€ 300,000.

## **Pubblicazioni**

La lista delle principali pubblicazioni e' allegata (allegato 1) al presente Verbale.

Successivamente, la commissione invita il candidato, Dott. Campanella, del quale viene accertata l'identità personale, come da foglio firma allegato al presente verbale, per la prova di idoneità didattica che, conformemente a quanto stabilito nella seduta preliminare, consiste in una lezione sul tema "Ruolo dei mitocondri nel metabolismo e morte cellulare" e che si svolge pubblicamente in collegamento telematico.

Terminata la prova, il candidato viene invitato ad uscire dalla riunione telematica.

La commissione formula il seguente giudizio collegiale in merito alla prova di idoneità didattica:

"Il candidato ha dimostrato eccellenti doti didattiche, esponendo con chiarezza e completezza l'argomento oggetto della lezione".

Al termine dei lavori, la commissione, con deliberazione assunta a unanimità, sulla base dei giudizi collegiali espressi, dichiara che il Dott. Michelangelo Campanella è valutato positivamente e quindi qualificato per ricoprire il posto di professore di ruolo di seconda fascia presso il Dipartimento di Biologia per il settore concorsuale 06/A2 e settore scientifico disciplinare MED/04.

Il presente Verbale è redatto in unico originale, siglato in ogni pagina e sottoscritto dal Prof. Roberto Testi, e corredato da dichiarazione di formale sottoscrizione per via telematica dagli altri componenti della commissione.

La commissione provvederà a consegnare il presente verbale al responsabile del procedimento Dott.ssa Annalisa De Cesare per i conseguenziali adempimenti.



Roma, 16 giugno 2022.

Letto ed approvato

Prof. Roberto Testi

A handwritten signature in black ink, appearing to be 'Roberto Testi', with a stylized, cursive script.

## Allegato 1

### PUBBLICAZIONI

1. Singh A, Strobbe D and **Campanella M**. Pyroptosis targeting via mitochondria: an educated guess to fast-track COVID-19 therapies. **Br J Pharmacol**. 2021 *in press*
2. Rigon M, Townley AR and **Campanella M**. Mitochondria ensure immune surveillance by retro-communication with the nucleus. **Cell Met**. (2021) doi.org/10.1016/j.cmet.2021.04.013
3. Frison M, Strobbe D, Faccenda D, Rigon M, Abeti R, Cash D, England-Rendon BS, Barnes K, Sadeghian M, Sajic M, Wells LA, Giunti P, Xia D, Smith K, Mortiboys H, Turkheimer F and **Campanella M**. The Translocator Protein (TSPO) is prodromal to mitophagy loss in Neurotoxicity. **Mol. Psychiatry** (2021). doi.org/10.1038/s41380-021-01050-z
4. Singh A, Faccenda D, **Campanella M**. Pharmacological advances in mitochondrial therapy. **EBioMedicine**. 2021 Mar;65:103244. doi: 10.1016/j.ebiom.2021.103244.
5. Klionsky DJ ...**Campanella M**....Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th Edition). **Autophagy**. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280
6. Strobbe D, Sharma S, **Campanella M**. Links between mitochondrial retrograde response and mitophagy in pathogenic cell signalling. **Cell Mol Life Sci**. 2021 Feb 23. doi: 10.1007/s00018-021-03770-5.
7. Desai R, East DA, Hardy L, Crosby J, Rigon M, Faccenda D, Alvarez MS, Singh A, Mainenti M, Kuhlman-Hussey L, Bentham R, Szabadkai G, Zappulli V, Dhoot G, Romano L, Xia D, Hamechar-Brady A, Chapple P, Fleck R, Vizcay-Barrena G, Smith K and **Campanella M**. Mitochondria form contact sites with the nucleus to couple prosurvival retrograde response. **Sci Adv** 2020 Dec 18;6(51):eabc9955. doi: 10.1126/sciadv.abc9955.
8. Conte O, Pecorari R, Strobbe D, Hendriks CMM, Wiezorek S, Faccenda D, Minutolo A, Montesano C, Bolm C and **Campanella M**. A novel pharmacological inhibitor of the mitochondrial F1Fo-ATPase represses proliferation of cancer cells. **Br J Pharmacol**. 2020 Oct 10. doi: 10.1111/bph.15279.
9. Faccenda D, Goring G, Baracca A, Solaini G and **Campanella M**. The ATPase Inhibitory Factor 1 (IF1) retroregulates the expression of the mitochondrial Ca<sup>2+</sup> uniporter (MCU) via the AMPK/CREB pathway. **Biochim Biophys Acta**. 2021 Jan;1868(1):118860. doi: 10.1016/j.bbamcr.2020.118860.
10. Faccenda D and Campanella M. Mitochondria as ligands in Paracrine Signalling of Neuronal Cells. **J Neuroimmune Pharmacol**. 2020 Dec;15(4):565-566. doi: 10.1007/s11481-020-09952-5.
11. Draper ACE, Wilson Z, Maile C, Faccenda D, **Campanella M**, Piercy RJ. Species-specific consequences of an E40K missense mutation in superoxide dismutase 1 (SOD1). **FASEB J**. 2020 Jan;34(1):458-473. doi: 10.1096/fj.201901455R
12. Wang X, Galli G and **Campanella M**. Mitochondrial pharmacology: featured mechanisms and approaches for therapy translation. **Br J Pharmacol**. 2019 Nov;176(22):4245-4246. doi: 10.1111/bph.14820
13. Simula L, **Campanella M**, Campello S. Targeting Drp1 and mitochondrial fission for therapeutic immune modulation. **Pharmacol Res**. 2019 Aug;146:104317. doi: 10.1016/j.phrs.2019.104317
14. Desai R and **Campanella M**. Targeting mitochondrial cholesterol (mChol) and oxysterol signalling for therapeutic intervention in neurological conditions. **Br J Pharmacol**. 2019 May 11. doi: 10.1111/bph.14697
15. D'Eletto M, Rossin F, Occhigrossi L, Farrace MG, Faccenda D, Desai R, Marchi S, Refolo G, Falasca L, Antonioli M, Ciccocanti F, Fimia GM, Pinton P, **Campanella M**, Piacentini M. Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. **Cell Rep** 2018 Dec 26;25(13):3573-3581.e4. doi: 10.1016/j.celrep.2018.11.094.
16. Singh A, Kendall SL, **Campanella M**. Common Traits Spark the Mitophagy/Xenophagy Interplay. **Front Physiol**. 2018 Sep 20;9:1172. doi: 10.3389/fphys.2018.01172.



17. Di Rita A, Peschiaroli A, D Acunzo P, Strobbe D, Hu Z, Gruber J, Nygaard M, Lambrughi M, Melino G, Papaleo E, Dengjel J, El Alaoui S, **Campanella M**, Dötsch V, Rogov VV, Strappazon F, Cecconi F. HUWE1 E3 ligase promotes PINK1/PARKIN-independent mitophagy by regulating AMBRA1 activation via IKK $\alpha$ . *Nat Commun*. 2018 Sep 14;9(1):3755. doi: 10.1038/s41467-018-05722-3.
18. Desai R and **Campanella M**. mitoCPR: meticulous monitoring of mitochondrial proteostasis. *Mol Cell*. 2018 Jul 5;71(1):8-9. doi: 10.1016/j.molcel.2018.06.027
19. Martín-Jiménez R, Faccenda D, Allen E, Reichel HB, Arcos L, Ferraina C, Strobbe D, Russell C, **Campanella M**. Reduction of ATPase Inhibitory Factor 1 (IF<sub>1</sub>) leads to visual impairment in vertebrates. *Cell Death Dis*. 2018 Jun 4;9(6):669. doi: 10.1038/s41419-018-0578-x.
20. Strobbe D and **Campanella M**. Anxiolytic therapy: a paradigm of successful mitochondrial pharmacology. *Trends Pharmacol Sci*. 2018 Mar 30. pii: S0165-6147(18)30046-4. doi: 10.1016/j.tips.2018.02.008.
21. Gatliff J, East D, Singh A, Frison M, Alvarez MS, Sampson N, Turkheimer F and **Campanella M**. A role for TSPO in Ca<sup>2+</sup> and Redox signalling. *Cell Death Dis*. 2017 8, e2896; doi:10.1038/cddis.2017.186
22. Strobbe D, Robinson AA, Harvey K, Rossi L, Ferraina C, de Biase V, Rodolfo C, Harvey RJ, **Campanella M**. Distinct mechanisms of pathogenic DJ-1 mutations in mitochondrial quality control. *Front Mol Neurosci*. 2018 Mar 15;11:68. doi: 10.3389/fnmol.2018.00068.
23. Hardy L, Frison M and **Campanella M**. Breast cancer cells exploit mitophagy to exert therapy resistance” *Oncotarget* 2018 Feb 19;9(18):14040-14041. doi: 10.18632/oncotarget.24533
24. Galluzzi L,...**Campanella M**...Kroemer G. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death & Differentiation* (2018) doi:10.1038/s41418-017-0012-4
25. Bultynck G and **Campanella M**. Tumor suppressive Ca<sup>2+</sup> signalling is driven by IP<sub>3</sub> receptor fitness. *Cell Stress* 73-78 | 10.15698/cst2017.11.109
26. Georgakopoulos ND, Frison M, Alvarez MS, Bertrand H, Wells G and **Campanella M**. Reversible Keap1 inhibitors are preferential pharmacological tools to modulate cell mitophagy. *Scientific Reports* 7, Article number: 10303(2017) doi:10.1038/s41598-017-07679-7
27. Gatliff J, East D, Singh A, Frison M, Alvarez MS, Sampson N, Turkheimer F and **Campanella M**. A role for TSPO in Ca<sup>2+</sup> and Redox signalling. *Cell Death Dis* 2017 8, e2896; doi:10.1038/cddis.2017.186 Published online 22 June 2017
28. Faccenda D, Nakamura J, Dooth G, Piacentini M, Yoshida M and **Campanella M**. Control of Mitochondrial Remodeling by the ATPase Inhibitory Factor 1 Unveils a Pro-survival Relay via OPA1. *Cell Rep*. 2017 Feb 21;18(8):1869-1883. doi: 10.1016/j.celrep.2017.01.070
29. Hawkins KE, Moschidou D, Faccenda D, Wruck W, Martin-Trujillo A, Hau KL, Ranzoni AM, Sanchez-Freire V, Tommasini F, Eaton S, De Coppi P, Monk D, **Campanella M**, Thrasher AJ, Adjaye J, Guillot PV. *Mol Ther*. 2017 Feb 1;25(2):427-442.
30. Georgakopoulos ND, Wells G and **Campanella M**. The Pharmacological Regulation of Cellular Mitophagy. *Nat Chem Biol*. 2017 Jan 19;13(2):136-146.
31. Matic I, Strobbe D, Di Guglielmo F and **Campanella M**. Molecular Biology Digest of Cell Mitophagy. *Int Rev Cell Mol Biol*. 2017;332:233-258. doi: 10.1016/bs.ircmb.2016.12.003. Epub 2017 Feb 23.
32. Beffagna G, Sammarco A, Bedin C, Romualdi C, Mainenti M, Mollo A, Cavicchioli L, Ferro S, Trez D, De Maria R, Nitti D, Sacconi A, **Campanella M**, Agostini M, Zappulli V. Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index. *PLoS One*. 2017 Jan 12;12(1):e0169454.
33. Liao C, Ashley N, Diot A, Morten K, Phadwal K, Williams A, Fearnley I, Rosser L, Lowndes J, Fratter C, Ferguson DJ, Vay L, Quaghebeur G, Moroni I, Bianchi S, Lamperti C, Downes SM, Sitarz KS, Flannery PJ, Carver J, Dombi E, East D, Laura M, Reilly MM, Mortiboys H, Prevo R, **Campanella M**, Daniels MJ, Zeviani M, Yu-Wai-Man P, Simon AK, Votruba M,

- Poulton J. Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations. **Neurology** 2017. Jan 10;88(2):131-142.
34. East DA, **Campanella M**. Mitophagy and the therapeutic clearance of damaged mitochondria for neuroprotection. **Int J Biochem Cell Biol**. 2016 Oct;79:382-387.
  35. Klionsky DJ ...**Campanella M**....Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy. **Autophagy**. 2016 Jan 2;12(1):1-222.
  36. Gatliff J and **Campanella M**. TSPO: kaleidoscopic 18kDa amid biochemical pharmacology, control and targeting of mitochondria. **Biochem J**. 2016 Jan 15;473(2):107-2. doi: 10.1042/BJ20150899.
  37. Campanella M. Mitochondrial Pharmacology: A need in Modern Biomedicine. **Pharmacol Res**. 2016 Jan;103:204-5. doi: 10.10
  38. Altuntas S, Rossin F, Marsella C, D'Eletto M, Diaz-Hidalgo L, Farrace MG, **Campanella M**, Antonioli M, Fimia GM and Piacentini M. The Pyruvate Kinase Isoenzyme M2 and Transglutaminase type 2 Interplay in Autophagy Regulation. **Oncotarget** 2015 Dec 24. doi: 10.18632/oncotarget.6759
  39. Chimeo C, Fernandez-Gimenez AV, **Campanella M**, Mendez-Romero O, Muhlia-Almazan A. The shrimp mitochondrial FoF 1-ATPase inhibitory factor 1 (IF1). **J Bioenerg Biomembr**. 2015 Oct;47(5):383-93. doi: 10.1007/s10863-015-9621-0.
  40. Matic I, Cocco S, Ferraina C, Martin-Jimenez R, Florenzano F, Crosby J, Lupi R Amadoro G, Russell C, Pignataro G, Annunziato L, Abramov AY and **Campanella M** Neuroprotective coordination of mitophagy by the F1Fo-ATPase Inhibitor Factor 1 (IF1). **Pharmacol Res**. 2015 Oct 17. pii: S1043-6618(15)00253-4.
  41. **Campanella M** and Turkheimer FE. TSPO: functions and applications of a mitochondrial stress response pathway. **Biochem Soc Trans**. 2015 Aug 1;43(4):593-4. Review.
  42. Gatliff J and **Campanella M**. TSPO is a REDOX regulator of Cell Mitophagy. **Biochem Soc Trans**. 2015 Aug 1;43(4):543-52. Review.
  43. **Campanella M**, TSPO the unrested: challenged opinions of a resourceful mitochondrial protein. **Trends Endocrinol Metab**. 2015 Jul;26(7):333-4
  44. Martin-Jimenez R, **Campanella M** and Russell C. Neuroscience Catch Of The Day: Zebrafish models of neurodegeneration. **Curr Neurol Neurosci Rep**. 2015 Jun;15(6):33. doi: 10.1007/s11910-015-0555-z
  45. Matic I, Strobbe D, Frison M and **Campanella M**. Control and impairment of Mitochondrial Quality in Neurons. **Pharmacol Res**. 2015 Apr 23. pii: S1043-6618(15)00060-2. doi: 10.1016
  46. Galluzzi L, ...**Campanella M**,...Kroemer G, Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. **Cell Death Differ**. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137.
  47. Strappazzon F, Nazio F, Corrado M, Cianfanelli V, Romagnoli A, Fimia GM, Campello S, Nardacci R, Piacentini M, **Campanella M**, Cecconi F. AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. **Cell Death Differ**. 2015 Mar;22(3):517. doi: 10.1038/cdd.2014.190.
  48. Gatliff, East D, Crosby J, Abeti R Harvey R, Craigen W, Parker P and **Campanella M**. TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. **Autophagy** 2014 Dec 2;10(12):2279-96. doi:10.4161/15548627.2014.991665.
  49. East D, Fagiani F, Crosby J, Bertrand H, Schaap M, Fowkes A, Wells G, and **Campanella M**. PML: a novel,  $\Delta\Psi$ m independent, Mitophagy Inducer". **Cell Chemical Biology**. 2014 Nov 20;21(11):1585-96. doi: 10.1016/j.chembiol.2014.09.019.
  50. **Campanella M**. Peptide targeting of mitochondria elicits testosterone formation. **Mol Ther**. 2014 Oct;22(10):1727-9. doi: 10.1038/mt.2014.171.
  51. Altuntas S, D'Eletto M, Rossin F, Farrace MG, Falasca L, Piredda L, Cocco S, Piacentini M and **Campanella M**. Transglutaminase Type 2, Mitochondria and Huntington's Disease: Menage a trois. **Mitochondrion** 2014 Nov;19 Pt A:97-104. doi: 10.1016/j.mito.2014.09.008.
  52. Strappazzon F, Nazio F, Corrado M, Cianfanelli V, Romagnoli A, Fimia GM, Campello S, Nardacci R, Piacentini M, **Campanella M**, Cecconi F. AMBRA1 is able to induce mitophagy



- via LC3 binding, regardless of PARKIN and p62/SQSTM1. **Cell Death Differ.** 2014 Sep 12. doi: 10.1038/cdd.2014.139.
53. Rossin F, D'Eletto M, Falasca L, Sepe S, Cocco S, Fimia GM, **Campanella M**, Mastroberardino PG, Farrace MG, Piacentini M. Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis. **Cell Death Differ.** 2014 Jul 25. doi: 10.1038/cdd.2014.106.
  54. Ivanovs, F, Allan E, Faccenda D, Ahmed AA, Gatiloff J, Russell C, Duchon MR and **Campanella M**. The Chemical Agent BTB06584 Targets the Reversion of the Mitochondrial F1Fo-ATP synthase mimicking IF1. **Br J Pharmacol.** 2014 Feb 15. doi: 10.1111/bph.12638
  55. Archacka K, Pozzobon M, Repele A, Rossi CA, **Campanella M** and De Coppi P. Culturing muscle fibers in hanging drops: a novel approach to solve an old problem. **Biol Cell.** 2014 Feb;106(2):72-82. doi: 10.1111/boc.201300028.
  56. **Campanella, M**. Neurodegeneration abides by the laws of Mitochondrial Biology. **European Journal of Neurodegenerative Diseases.** Volume1, issue 2 Nov 11, 2014
  57. Amadoro G, Corsetti N, Florenzano F, Atlante A, Ciotti MT, Mongiardi MP, Bussani R, Nicolin V, Nori SL, **Campanella M**, Calissano P. AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons. **Neurobiol Dis.** 2014 Feb;62:489-507. doi: 10.1016/j.nbd.2013.10.018.
  58. **Campanella M**, Klionsky DJ. Keeping the engine clean: A mitophagy task for cellular physiology. **Autophagy.** 2013 22;9(11).
  59. East D and **Campanella M**. Ca<sup>2+</sup> in quality control: an unresolved riddle critical to autophagy and mitophagy. **Autophagy** 2013 22;9(11).
  60. Lefebvre V, Du Q, Bair S, Cheuk-Him Ng A, Eric Shoubridge, **Campanella M**, McBride HM, Screatton RA. The ATPase Inhibitory Factor 1 (IF1) is required for PARKIN recruitment to mitochondria and mitophagy. **Autophagy.** 2013 22;9(11).
  61. Faccenda D, Tan CH, Duchon MR, **Campanella M**. Mitochondrial IF 1 preserves cristae structure to limit apoptotic cell death signaling. **Cell Cycle.** 2013 15;12(16):2530-2. doi: 10.4161/cc.25840.
  62. Iannetti L, Abbouda A, Fabiani C, Zito R, **Campanella M**. Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report. **J Med Case Rep.** 2013 26;7(1):199. doi: 10.1186/1752-1947-7-199.
  63. Repele A, Lupi R, Eaton S, De Coppi P and **Campanella M**. Fundamental Cell Biology sets the Differences between Subpopulations of Satellite Cells (SCs). **BMC Cell Biol.** 2013 3;14(1):24.
  64. Chlystun M, **Campanella M**, Law A, Duchon MR, Fatimathas L, Levine T, GerkeV, Moss S. Regulation of Mitochondrial Morphogenesis by Annexin A6. **Plos One** 2013;8(1):e53774. doi:10.1371/journal.pone.005377
  65. Vara DS, **Campanella M**, Dunn WB, Pizzorno G, Hirano M, Pula G. Autocrine amplification of integrin  $\alpha\text{IIb}\beta 3$  activation and platelet adhesive responses by deoxyribose-1- phosphate. **Thromb Haemost.** 2013 14;109(5).
  66. Faccenda D, Tan CH, Seraphim A, Duchon MR & **Campanella M**. The F1Fo-ATPase endogenous inhibitor IF1 regulates Mitochondrial Commitment to Apoptosis. **Cell Death Differ.** 2013;20(5):686-97. doi: 10.1038/cdd.2012.163.
  67. Shah DI, Takahashi-Makise N, Cooney JD, Li L, Schultz IJ, Pierce EL, Narla A, Seguin A, Hattangadi SM, Medlock AE, Langer NB, Dailey TA, Hurst SN, Faccenda D, Wiwczar JM, Heggors SK, Vogin G, Chen W, Chen C, Campagna DR, Brugnara C, Zhou Y, Ebert BL, Danial NN, Fleming MD, Ward DM, **Campanella M**, Dailey HA, Kaplan J, Paw BH. Mitochondrial Atpif1 regulates heme synthesis in developing erythroblasts. **Nature.** 2012 22;491(7425):60812.
  68. Iannetti L, Paroli MP, Fabiani C, **Campanella M**, Pivetti-Pezzi P. Effects of Intravitreal Bevacizumab on Inflammatory Choroidal Neovascular Membrane. **Eur J Ophthalmol.** 2012 8:0. doi: 10.5301/ejo.5000192.
  69. Klionsky DJ ...**Campanella M**....Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy. **Autophagy.** 2012 8(4):445-544.

70. Faccenda D and **Campanella M**. Molecular Regulation of the Mitochondrial F1Fo ATPsynthase: Physiological and Pathological Significance of the Inhibitor Factor 1 (IF1). *Int J Cell Biol*. 2012;2012:367934.
71. **Campanella, M**. Neurodegeneration abides by the laws of Mitochondrial Biology. 2012 *European Journal of Neurodegenerative Diseases* Vol. 1, No 2, 2012.
72. Varaa DS, **Campanella M** and Pula G. The NOX1-selectiveinhibitor 2-acetylphenothiazine inhibits superoxide ion generation in human platelets and impairs collagen--dependent thrombus formation. *Br J Pharmacol*. 2013 168(1):212-24. doi: 10.1111/j.14765381.2012.02130.
73. Plun-Favreau H, Burchell VS, Holmström KM, Yao Z, Deas E, Cain K, Fedele V, Moiso N, **Campanella M**, Miguel Martins L, Wood NW, Gourine AV, Abramov AY HtrA2 deficiency causes mitochondrial uncoupling through the F1F0-ATPsynthase and consequent ATP depletion. *Cell Death and Disease*. 2012 28;3:e335.
74. Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy A, Dinsdale D, Condorelli F, Brandner S, Tulchinsky E, Grose R, **Campanella M**, Jones C, Salomoni P. The autophagy associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. *Oncogene*. 2013 7;32(6):699-712. doi: 10.1038/onc.2012.111. Epub 2012 Apr 23.
75. Gatliff J and **Campanella M**. The 18Kda Translocator Protein (TSPO): a New Perspective in Mitochondrial Biology. *Curr Mol Med*. 2012 12(4):356-68.
76. Severinatne M, Faccenda D, De Biase V & **Campanella M**. In Bcl-2 knock-down cells, PK11195 inhibits mitophagy targeting the F1Fo-ATPsynthase. *Curr Mol Med*. 2012 12(4):476-82.
77. **Campanella M**. The Physiology and Pharmacology of the mitochondrial 18-Kd Translocator Protein (TSPO): an Emerging Molecular Target for Diagnosis and Therapy. *Curr Mol Med*. 2012;12(4):355.
78. Iannetti L, Accorinti M, Malagola R, Bozzoni-Pantaleoni F, Da Dalt S, Nicoletti F, Gradini R, Traficante A, **Campanella M**, Pivetti-Pezzi P. Role of the intravitreal growth factors in the pathogenesis of idiopathic epiretinal membrane. *Invest Ophthalmol Vis Sci*. 2011 52:57869 PMID: 21693611.
79. Pula G, Garonna E, Dunn WB, Hirano M, Pizzorno G, **Campanella M**, Schwartz EL, El Kouni MH, Wheeler-Jones CP. Paracrine stimulation of endothelial cell motility and angiogenesis by platelet-derived deoxyribose-1-phosphate. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2010;30(12):26318.
80. Gastaldello A, Gami P, Callaghan H & **Campanella M**. Ca<sup>2+</sup> dependent autophagy is enhanced by the Pharmacological Agent PK11195. *Autophagy* July 6;6(5). 2010.
81. Hall A, **Campanella M**, Loesch A, Duchen M, and Unwin R. "Albumin endocytosis in OK cells exposed to rotenone: an "OKay" model for the effects of mitochondrial dysfunction on the proximal tubule?" *Nephron Physiol*. 12;115(2) 2010.
82. Pavlov E, Aschar-Sobbi R, **Campanella M**, Turner RJ, Gomez-Garcia MR, Abramov AY. Inorganic polyphosphate and energy metabolism in mammalian cells. *J Biol Chem* 2010 Mar 26;285(13):9420-8.
83. Rossi CA, Pozzobon M, Ditadi A, Archacka K, Gastaldello A, Sanna M, Franzin C, Malerba A, Milan G, Cananzi M, Schiaffino S, **Campanella M\***, Vettor R, De Coppi P. Clonal characterization of muscle satellite cells: proliferation, metabolism and differentiation define an intrinsic heterogeneity. *Plos One* 2010 1;5(1):e8523. \*Corresponding/Senior author.
84. Ferrari D#, Pinton P#, **Campanella M##**, Callegari MG, Pizzirani C, Rimessi A, Di Virgilio F, Pozzan T, Rizzuto R. Functional and structural alterations in the Endoplasmic Reticulum and mitochondria during apoptosis triggered by C2-ceramide and CD95/APO-1/FAS receptor stimulation. *Biochem Biophys Res Commun*. 2010 Jan 1;391(1):575-81. #Equally contributed;\*Corresponding author.
85. **Campanella M**, Parker N, Tan CH, Hall AM and Duchen MR. IF1: setting the pace of the F1Fo-ATPsynthase. *Trends Biochem Sci*. 2009 Jul;34(7):343-50. doi: 10.1016/j.tibs.2009.03.006. Review.

*AP*

86. **Campanella M**, Seraphim A, Abeti R, Casswell E, Echave P, Duchen MR. IF1, the endogenous regulator of the F(1)F(o)-ATP synthase, defines mitochondrial volume fraction in HeLa cells by regulating autophagy. **Biochim Biophys Acta**. 2009 May;1787(5):393-401. doi: 10.1016/j.bbabo.2009.02.023.
87. **Campanella M\***, Szabadkai G and Rizzuto R. Modulation of Intracellular Ca<sup>2+</sup> Signalling in HeLa Cells by the Apoptotic Cell Death Enhancer PK11195. **Biochem. Pharmacol**. 2008 1;76(11):1628-36. \*Corresponding author.
88. **Campanella M**, Farah Z, Casswell E, Chong S, Wieckowski MR, Abramov AY, Tinker A and Duchen MR. Regulation of Mitochondrial Structure and Function by the F(1)F(o)-ATPase Inhibitor Protein, IF(1). **Cell Metabolism** 2008 Jul;8(1):13-25.
89. McKenzie M, Liolitsa D, Akinshina N, **Campanella M**, Sisodiya S, Hargreaves I, Nirmalananthan N, Sweeney MG, Abou-Sleiman PM, Wood NW, Hanna MG, Duchen MR. Mitochondrial ND5 gene variation associated with encephalomyopathy and mitochondrial ATP consumption. **J Biol Chem**, 2007 21;282(51):36845-52.
90. Hoyer-Hansen M, Bastholm L, Szyniarowski P, **Campanella M**, Szabadkai G, Farkas T, Bianchi K, Fehrenbacher N, Elling F, Rizzuto R, Mathiasen IS, Jaattela M. Control of macroautophagy by calcium, calmodulin dependent kinase kinases and Bcl-2. **Mol. Cell**. 2007 25(2):193-205).
91. **Campanella M**, Pinton P, Rizzuto R. Mitochondrial Ca<sup>2+</sup> homeostasis in health and diseases. **Biological Research**, 2004;37(4):653-60.
92. Chami M, Prandini A, **Campanella M**, Pinton P, Szabadkai G, Reed JC and Rizzuto R. Bcl-2 and Bax exert opposing effects on Ca<sup>2+</sup> signaling, which do not depend on their putative pore-forming region. **J Biol Chem** 2004 Dec 24;279(52):54581-9.
93. **Campanella M**, de Jong AS, Lanke KW, Melchers WJ, Willems PH, Pinton P, Rizzuto R, van Kuppeveld FJ. (2004). The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca<sup>2+</sup> homeostasis. **J Biol Chem** 2004 Apr 30;279(18):18440-50.
94. Aguiari G\*, **Campanella M\***, Manzati E, Pinton P, Banzi M, Moretti S, Rizzuto R, del Senno L. Expression of polycystin-1 C-terminal fragment enhances the ATP-induced Ca<sup>2+</sup> release in human kidney cells. **Biochemical Biophysical Research Communication** 2003 301: 657-664.\* These two authors contributed equally to this work.
95. Ferrari D, Pinton P, Szabadkai G, Chami M, **Campanella M**, Pozzan T, Rizzuto R. Endoplasmic reticulum, Bcl-2 and Ca<sup>2+</sup> handling in apoptosis. **Cell Calcium** 2002 32(5-6):413--20.

